Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 45

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 45
---
 June 30, 

    2025  
    2024  
    2025  
    2024 
  
    Research and development 
    $59,867  
    $221,661  
    $129,529  
    $439,480 
  
    General and administrative 
     120,896  
     561,191  
     292,125  
     1,118,063 
  
    Total stock-based compensation expense 
    $180,763  
    $782,852  
    $421,654  
    $1,557,543 

As
of June 30, 2025, total compensation cost not yet recognized related to unvested stock options was approximately $0.6 million, which
is expected to be recognized over a weighted-average period of approximately 1.2 years.

The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the six months ended June 30, 2025, are presented in the table
below. The weighted average fair value of stock options granted during the six months ended June 30, 2025 was $8.14 per share.

 SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED 

    2025 
  
    Exercise price 
    $9.24 
  
    Expected term (in years) 
     5.5 
  
    Volatility 
     128.4%
  
    Risk free rate 
     4.1%
  
    Dividend yield 
     0%

The
following table presents the exercise price of outstanding stock options as of June 30, 2025:

 SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS 

    Exercise price 
    Options  outstanding 

    $0.01 - $80.00 
     56,047 
  
    $0.01 - $80.00 
     56,047 

    $80.01 or higher 
     48,619 
  
    Total 
     104,666 

NOTE
6: CAPITALIZATION

    a.
    As